CORONABSECorona Remedies LtdMinimalNeutral
Announced Tue, 12 May · 16:02 IST

Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026

CORONA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+9.0%1-day move
₹1640.00
prior close
₹1663.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.2+0.2-0.4-0.5+9.0+7.0+11.0+8.4+5.2+2.7+3.7+5.3+25.6
Up moveDown movePending
AI summary

Corona Remedies Limited has filed its Annual Secretarial Compliance Report for FY 2026, prepared by Practicing Company Secretary Dhara Patel. The report covers compliance review of all applicable SEBI regulations including LODR, ICDR, SAST, PIT, and Depositories regulations. The company has received a clean report with 'Yes' compliance across all 12 checkpoints covering secretarial standards, board processes, policy updation, website disclosures, director disqualification checks, document preservation, performance evaluation, related party transactions, event disclosures, and insider trading regulations. No actions have been taken by SEBI or stock exchanges against the company. No deviations, fines, or non-compliances were observed. The company maintains proper Board processes and compliance mechanisms as certified by the practicing CS.

Likely market impact

Clean compliance report indicates strong corporate governance and regulatory adherence. No red flags for investors. The company appears well-managed from a regulatory compliance perspective.